This trial is active, not recruiting.

Condition kidney transplantation
Sponsor Ramathibodi Hospital
Start date May 2009
End date January 2015
Trial size 200 participants
Trial identifier NCT00903578, KT-1


The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective

Primary Outcomes

Progression of allograft dysfunction and all-cause Mortality
time frame: 3 and 5 years

Secondary Outcomes

Relationship of FGF-23 and 25-OH-D, 1-25-OH-D, PTH, calcium, phosphate, urine phosphate and eGFR
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - at least one year post-transplantation - no more than 10% increase in serum creatinine for the past 3 months Exclusion Criteria: - refuse to participate in the study - any acute illnesses

Additional Information

Official title Impact of FGF-23 and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients
Principal investigator Sinee Disthabanchong, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in December 2009.
Information provided to ClinicalTrials.gov by Ramathibodi Hospital.